Attention Deficit Hyperactivity Disorder (ADHD) is a global problem, estimated to affect over 37 million people in the seven major markets (US, France, Germany, Spain, Italy, Japan, and the UK). The CDC reports that ADHD prevalence amongst children is as high as 10% and among adults it is 5%. ADHD is associated with a significant cost burden, estimated at up to $52 billion in the US alone.
Today, no single physical, laboratory or imaging test exists to reliably diagnose ADHD. A diagnosis commonly relies only on subjective assessment of behavioral symptoms, together with physiological EEG measures and a medical exam to rule out other causes for symptoms. As a result, many professionals believe that the disorder is over-diagnosed in some but under-diagnosed in others.
elminda has completed two clinical studies, demonstrating the potential utility of BNA™ technology in ADHD severity grading and treatment management. The BNA™ approach has potential use as an objective electrophysiological marker in ADHD patients although additional research and validation is required.
 Introducing a novel approach of network oriented analysis of ERPs, demonstrated on adult attention deficit hyperactivity disorder. G. Shahaf, A. Reches, N. Pinchuk , T. Fisher, G. Ben Bashat, A. Kanter, I. Tauber, D. Kerem, I. Laufer, J. Aharon-Peretz, H. Pratt, A.B. Geva. Clin Neurophysiol. 2012 Aug;123(8):1568-80.